Biotechnology

Kairos Pharma to Participate in The Microcap Conference in January 2025

December 16, 2024 12:15 PM

Kairos Pharma, (NYSE American:KAPA) a clinical stage biotechnology company is pleased to announce its participation in The Microcap Conference 2025, the premier event for growth-focused companies and investors. The conference will take place January 28-30, 2025, at the Borgata Hotel Spa & Casino in Atlantic City, NJ. Kairos Pharma's management team will deliver a corporate presentation and engage in one-on-one meetings with institutional and...

Read more

“Greenwashing is Slowing Down the Energy Transition”: ThinkEnergy Urges a Shift Toward Genuine Solutions Driving Energy Transition

December 16, 2024 10:00 AM

As sustainability becomes a strategic priority for companies, it is alarming that 85% of global investors consider greenwashing a growing problem, according to EY's 2024 Institutional Investor Survey. This phenomenon not only undermines the credibility of environmental initiatives but also diverts critical resources away from projects that can make a real difference in combating climate change. Check out the EY's 2024 Institutional Investor...

Read more

Scailyte and Visterra Partner to Advance Autoimmune Disease Research

December 16, 2024 9:30 AM

BASEL, SWITZERLAND and WALTHAM, MA / ACCESSWIRE / December 16, 2024 / Scailyte AG, an AI-driven biomarker discovery company, and Visterra, Inc., a clinical-stage biopharmaceutical company, today announced a research collaboration with the goal to accelerate the development of innovative treatments for autoimmune diseases. The collaboration will leverage Scailyte's proprietary AI platform, ScaiVision®, and Visterra's expertise in biologics...

Read more

Xenetic Biosciences, Inc. Extends Research Agreement with the University of Virginia for the Advancement of its DNase-Based Oncology Platform

December 16, 2024 9:00 AM

Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immuno-oncology technologies addressing hard to treat cancers, today announced it has extended its previously announced Research Funding Agreement (the "Agreement") with the University of Virginia ("UVA") to advance the development of its systemic DNase program through 2025. Xenetic's DNase-based oncology platform...

Read more

Nabu Joins The Microcap Conference 2025 to Showcase AI Innovations in SEC Reporting

December 16, 2024 9:00 AM

Nabu, an AI tool that streamlines SEC reporting for public companies, is pleased to announce its participation in The Microcap Conference 2025, the premier event for growth-focused companies and investors. The conference will take place January 28-30, 2025, at the Borgata Hotel Spa & Casino in Atlantic City, NJ. Nabu's management team will deliver a corporate presentation and engage in one-on-one meetings with institutional investors and public...

Read more

enVVeno Medical Successfully Completes Final Wave of Implants in Pre-Clinical GLP Study for enVVe

December 16, 2024 8:50 AM

enVVeno Medical Corporation (Nasdaq:NVNO) ("enVVeno" or the "Company"), a company setting new standards of care for the treatment of venous disease, today announced the successful completion of the final wave of implants for shorter-term subjects in its six-month pre-clinical GLP study for enVVe, its transcatheter-delivered replacement venous valve. The successful completion of all planned implants in the GLP study, including both long-term and...

Read more

Tharimmune Announces Phase 2 Study Plan for TH104 in Patients With Moderate-to-Severe Pruritus Associated With Primary Biliary Cholangitis and Provides a Business Update

December 16, 2024 8:00 AM

Tharimmune, Inc. (Nasdaq:THAR) ("Tharimmune" or the "Company"), a clinical-stage biotechnology company committed to pioneering therapies in immunology and inflammation, today announced plans for initiating a Phase 2 study evaluating TH104 in patients suffering from moderate-to-severe pruritus (severe itching) associated with primary biliary cholangitis (PBC), a rare and chronic liver disease, and also provided a corporate update. The launch of...

Read more

Elizabeth Fraley, CEO of Kinder Ready Introduces Executive Functioning (EF) Course, Boost Academic and Life Skills in Young Learners

December 13, 2024 4:30 AM

SANTA MONICA, CA / ACCESSWIRE / December 13, 2024 / Moving towards innovation, Elizabeth Fraley, CEO of Kinder Ready unveils an executive functioning (EF) course for early learners in a variety of areas, including planning, organization, self-control, task initiation, time management, metacognition, working memory, attention, flexibility, and perseverance. This holistic approach helps students learn the basic study and organizational skills they...

Read more

Last Day of Trading in Warrants Series TO 9 in Alligator Bioscience AB is 13 December 2024

December 13, 2024 2:20 AM

LUND, SE / ACCESSWIRE / December 13, 2024 / Alligator Bioscience (STO:ATORX) 13 December 2024 is the last day of trading in warrants series TO 9 in Alligator Bioscience AB ("Alligator Bioscience" or the "Company"). Subscription of ordinary shares by exercise of warrants series TO 9 is ongoing until 18 December 2024. One (1) warrant series TO 9 entitles the holder to subscribe for one (1) new ordinary share in the Company at a subscription price...

Read more

Introducing the HyperCAM Delta: The Revolutionary High Throughput HD-MEA, for Faster, More Accurate Data Collection

December 12, 2024 10:00 AM

The HyperCAM Delta is setting a new standard in High-Density Multi-Electrode Arrays (HD-MEAs), being the world's first to offer simultaneous recording from all wells and all electrodes in a 24-well format. Unlike currently available platforms that record from wells sequentially, the HyperCAM Delta empowers researchers to collect data from all 24 wells simultaneously, drastically reducing experimental times and simplifying workflows. Why Choose...

Read more

CIL Announces Breakthrough in Benzene Recovery, Addressing Cost, Environmental, and Supply Challenges for OLED Display Manufacturers

December 12, 2024 9:00 AM

TEWKSBURY, MA / ACCESSWIRE / December 12, 2024 / Cambridge Isotope Laboratories, Inc. (CIL) has successfully developed and implemented a game-changing benzene-d6 recovery program, addressing major pain points for manufacturers of organic light-emitting diode (OLED) displays. This innovative service reduces costs, minimizes environmental impact, and conserves scarce deuterium supplies. OLED display producers rely heavily on deuterated benzene...

Read more

TuHURA Biosciences, Inc. Enters into Definitive Merger Agreement to Acquire Kineta, Inc.

December 12, 2024 8:45 AM

TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA"), a Phase 3 registration-stage immune-oncology company developing novel technologies to overcome resistance to cancer immunotherapy, and Kineta, Inc. (OTC PINK:KANT) ("Kineta"), a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology that address cancer immune resistance, today announced that they have entered into a definitive merger agreement in...

Read more

Bionoid Pharma, Inc. Moves to Expand E-Commerce Presence With Binding Agreement to Acquire Platform From Vitawin Supplements Ltd.

December 12, 2024 7:30 AM

Bionoid Pharma, Inc. ("Bionoid") (OTC PINK:BINP) is pleased to announce the signing of a Binding Letter of Intent (LOI) with Vitawin Supplements Ltd. to acquire its premier e-commerce platform, PrimeEnduro.com. This acquisition represents a significant milestone in Bionoid's strategic plan to expand its presence in the health and wellness sector through a scalable and AI-enhanced e-commerce ecosystem. The LOI outlines that Bionoid will retain...

Read more

BioInvent Announces First Patient Enrolled in Phase 1b/2a Study of BI-1607 in Combination with Ipilimumab and KEYTRUDA (Pembrolizumab) in Patients with Unresectable or Metastatic Melanoma

December 12, 2024 2:20 AM

Study to evaluate safety and anti-tumoral activity of anti-FcgRIIB antibody BI-1607 with anti-CTLA-4: ipilimumab, in combination with MSD's (Merck & Co., Inc., Rahway, NJ, USA)( anti-PD-1 therapy, KEYTRUDA® (pembrolizumab); initial data expected in H2 2025 Data from Phase 1 study in combination with trastuzumab previously demonstrated BI-1607 is safe, well tolerated and achieves full receptor occupancy during the treatment interval at several...

Read more

Agreement Signed with US Insurance Giant and Expanded Market

December 12, 2024 2:20 AM

UPPSALA, SE / ACCESSWIRE / December 12, 2024 / Biovica International (STO:BIOVIC-B)(STO:BIOVIC.B)(FRA:9II) SEK t Q2 24/25 Q2 23/24 May-Oct 24/25 May-Oct 23/24 Full year 23/24 Net sales 2,312 2,563 4,027 4,316 7,290 Operating profit (loss) -19,753 -25,316 -43,316 -57,508 -126,845 Profit (loss) for the period -21,152 -25,684 -44,041 -57,949 -124,823 Earnings per share, after dilution -0.23 -0.56 -0.50 -1.27 -2.14 Average number of shares during...

Read more

CARDIO inCode Publication in International Journal of Cardiology Cardiovascular Risk and Prevention

December 11, 2024 8:00 AM

GENinCode U.S., the genetics company focused on the prevention of cardiovascular disease, announces the publication in the International Journal of Cardiology Cardiovascular Risk and Prevention of a clinical research study on the ‘Interplay between Lifestyle Factors and Polygenic Risk for Incident Coronary Heart Disease in a Large Multiethnic Cohort' 1. The publication investigated a subset of over 60,000 adult individuals with no history of...

Read more

Tharimmune Announces $2.02 Million Private Placement to Advance Development Programs

December 6, 2024 4:15 PM

Tharimmune, Inc. (Nasdaq:THAR) ("Tharimmune" or the "Company"), a clinical-stage biotechnology company committed to pioneering therapies in immunology and inflammation, today announced it has entered into a securities purchase agreement to raise gross proceeds of approximately $2.02 million through a private placement. The agreement includes the issuance of 961,446 shares of common stock (or common stock equivalents) and warrants to purchase up...

Read more

ProteinQure to Present Data on PQ203, a Novel Peptide-Drug Conjugate for Triple Negative Breast Cancer, at 2024 San Antonio Breast Cancer Symposium

December 6, 2024 12:30 PM

TORONTO, ON / ACCESSWIRE / December 6, 2024 / ProteinQure, the leading company in computational design of peptide therapeutics, will be presenting compelling new data on the progress of their lead triple negative breast cancer (TNBC) drug PQ203 (December 12, 2024 presentation ID: P4-12-17) at the 2024 San Antonio Breast Cancer Symposium. PQ203 is a novel Peptide Drug Conjugate composed of a Sortilin receptor targeting peptide conjugated to the...

Read more

Biovica CLIA Lab Achieves New York State Permit that Opens the Entire US Market

December 6, 2024 2:20 AM

UPPSALA, SE / ACCESSWIRE / December 06, 2024 / Biovica International (STO:BIOVIC-B)(STO:BIOVIC.B) (FRA:9II) Biovica, active in blood-based cancer monitoring, today announces that the company has obtained an out-of-state permit allowing Biovica to offer testing to patients in New York State. Together with previous permits, Biovica is now allowed to offer DiviTum® TKa in all 50 states in the US and Puerto Rico. The permit was granted by the New...

Read more

Axonia Medical Announces Exclusive Partnerships with Leading Biotechnology and Microbiology Equipment Manufacturers

December 5, 2024 12:30 PM

SINGAPORE, SINGAPORE / ACCESSWIRE / December 5, 2024 / Axonia Medical is a leading provider of lab equipment. The company is excited to announce its exclusive partnerships. These partnerships are with well-known manufacturers in the biotechnology and microbiology fields. Axonia Medical collaborates with major companies. These include Abbott, Beckman Coulter, Sysmex, Roche, Bio-Rad, Mindray, Siemens, Horiba, and Perkin Elmer. This helps labs...

Read more